DE10075011I2 - Rezeptoren für Tumornekrosisfaktor-alpha und-beta. - Google Patents

Rezeptoren für Tumornekrosisfaktor-alpha und-beta.

Info

Publication number
DE10075011I2
DE10075011I2 DE2000175011 DE10075011C DE10075011I2 DE 10075011 I2 DE10075011 I2 DE 10075011I2 DE 2000175011 DE2000175011 DE 2000175011 DE 10075011 C DE10075011 C DE 10075011C DE 10075011 I2 DE10075011 I2 DE 10075011I2
Authority
DE
Germany
Prior art keywords
necrosis factor
tumor necrosis
receptors
beta
factor alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2000175011
Other languages
German (de)
English (en)
Other versions
DE10075011I1 (de
Inventor
Craig Smith
Raymond Goodwin
Patricia Beckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10075011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DE10075011I1 publication Critical patent/DE10075011I1/de
Application granted granted Critical
Publication of DE10075011I2 publication Critical patent/DE10075011I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE2000175011 1989-09-11 1990-09-10 Rezeptoren für Tumornekrosisfaktor-alpha und-beta. Active DE10075011I2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40537089A 1989-09-11 1989-09-11
US42141789A 1989-10-13 1989-10-13
US07/523,635 US5395760A (en) 1989-09-05 1990-05-10 DNA encoding tumor necrosis factor-α and -β receptors

Publications (2)

Publication Number Publication Date
DE10075011I1 DE10075011I1 (de) 2003-06-12
DE10075011I2 true DE10075011I2 (de) 2004-08-12

Family

ID=27410621

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2000175011 Active DE10075011I2 (de) 1989-09-11 1990-09-10 Rezeptoren für Tumornekrosisfaktor-alpha und-beta.
DE69024291T Expired - Lifetime DE69024291T2 (de) 1989-09-11 1990-09-10 Rezeptoren für Tumornekrosisfaktor-alpha und -beta

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69024291T Expired - Lifetime DE69024291T2 (de) 1989-09-11 1990-09-10 Rezeptoren für Tumornekrosisfaktor-alpha und -beta

Country Status (9)

Country Link
US (2) US5395760A (fr)
EP (1) EP0418014B1 (fr)
AT (1) ATE131871T1 (fr)
DE (2) DE10075011I2 (fr)
DK (1) DK0418014T3 (fr)
ES (1) ES2080809T4 (fr)
GR (1) GR3019333T3 (fr)
LU (1) LU90591I2 (fr)
NL (1) NL300008I2 (fr)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US6479632B1 (en) 1988-09-12 2002-11-12 Yeda Research And Development Co. Ltd. Tumor necrosis factor inhibitory protein and its purification
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
DE69017753T3 (de) * 1989-05-18 2013-06-20 Yeda Research And Development Co., Ltd. Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
EP0486526B2 (fr) * 1989-08-07 2001-03-07 Peptech Limited Ligands de liaison du facteur de necrose de tumeurs
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
EP1132471A3 (fr) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag Protéines liant le TNF
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
ES2120949T4 (es) * 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
ES2123515T3 (es) * 1991-03-29 1999-01-16 Immunex Corp Antagonistas de citoquinas a base de proteinas virales aisladas.
CA2585487A1 (fr) * 1991-04-17 1992-10-29 Medarex Inc. Polypeptides hydrosolubles ayant une haute affinite pour les interferons .alpha. et .beta.
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
DE69230862T2 (de) * 1991-10-15 2000-12-14 Michael F. Mullarkey Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
PT639079E (pt) * 1992-04-30 2000-04-28 Amgen Inc Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US20050255104A1 (en) * 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
CA2125763C (fr) * 1993-07-02 2007-08-28 Maurice Kent Gately Homodimere p40 de l'interleukine-12
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US6579697B1 (en) * 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US5708142A (en) * 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5741667A (en) * 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US8110659B1 (en) 1995-03-15 2012-02-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
US7078493B1 (en) 1995-03-15 2006-07-18 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like genes
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
ZA966663B (en) * 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6410252B1 (en) 1995-12-22 2002-06-25 Case Western Reserve University Methods for measuring T cell cytokines
WO1997033904A1 (fr) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Recepteurs contenant un domaine de mort cellulaire
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
AU2213697A (en) * 1996-03-18 1997-10-10 Medical Science Systems, Inc. A method for periodontal disease treatment
US5912141A (en) * 1996-05-22 1999-06-15 President & Fellows Of Harvard College Nucleic acids encoding tumor virus susceptibility genes
AU723355B2 (en) * 1996-05-23 2000-08-24 Scripps Research Institute, The MHC class II antigen presenting systems and methods for activating CD4+ T cells
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5939281A (en) * 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
CA2270913C (fr) * 1996-10-30 2011-05-24 Human Genome Sciences, Inc. Recepteur tr2 du facteur de necrose tumorale chez l'homme
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
EP0938548B1 (fr) 1996-11-06 2008-08-06 The Regents of the University of California Enzyme isolee, liberant le recepteur du facteur necrosant des tumeurs, compositions contenant cette enzyme et procede d'utilisation de celles-ci
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
JP2001506982A (ja) 1996-11-27 2001-05-29 イミュネックス・コーポレーション 一酸化窒素産生の制御法
JP2001513754A (ja) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
CA2273852C (fr) 1996-12-06 2009-09-29 Amgen Inc. Therapie combinee utilisant un inhibiteur de l'il-1 pour traiter les maladies induites par l'il-1
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1998054201A1 (fr) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Proteine 8 apparentee au recepteur du facteur de necrose tumorale humain
WO1999037818A1 (fr) * 1998-01-27 1999-07-29 Millennium Pharmaceuticals, Inc. Nouvelles molecules de la superfamille du recepteur du facteur de necrose tumorale et leurs utilisations
US20030180310A1 (en) * 1998-04-29 2003-09-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US7115557B2 (en) * 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030187196A1 (en) * 1998-12-30 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
DK1180159T3 (da) * 1999-05-28 2008-11-17 Targeted Genetics Corp Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
EP1939300A1 (fr) 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US7122631B2 (en) * 2000-02-22 2006-10-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2401683A1 (fr) 2000-03-02 2001-09-07 Xencor Conception et decouverte de variants du tnf-.alpha. a base de proteines destines au traitement des pathologies liees au tnf-.alpha.
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
DE01973455T1 (de) 2000-09-22 2004-04-22 Immunex Corp., Seattle Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
WO2002069232A2 (fr) 2001-02-19 2002-09-06 Merck Patent Gmbh Procede d'identification d'epitopes de lymphocytes t et utilisation dans la preparation de molecules a immunogenicite reduite
US20030040119A1 (en) * 2001-04-11 2003-02-27 The Regents Of The University Of Michigan Separation devices and methods for separating particles
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
WO2003026695A1 (fr) * 2001-09-21 2003-04-03 Genset S.A. Agonistes et antagonistes de cylixine permettant de traiter des troubles du metabolisme
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1463942B2 (fr) * 2001-12-21 2012-06-20 Immunex Corporation Methodes de purification d'une proteine
ES2311094T3 (es) 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
AU2003220529B2 (en) 2002-03-27 2006-09-07 Immunex Corporation Methods for increasing polypeptide production
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2004050683A2 (fr) * 2002-12-02 2004-06-17 Abgenix, Inc. Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
NZ546347A (en) 2003-10-14 2009-11-27 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
PL1949915T3 (pl) * 2004-04-30 2013-04-30 Biopheresis Tech Inc Sposób i układ do usuwania rozpuszczalnych TNFR1, TNFR2 i IL2R u pacjentów
AU2005273968A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
EP1909831A4 (fr) 2005-06-14 2013-02-20 Amgen Inc Préparations de protéines à tamponnage spontané
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
CA2629323A1 (fr) * 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Oligomeres permutant l'epissage destines a la superfamille des recepteurs tnf et leur utilisation lors de traitements de maladies
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
CA2652858A1 (fr) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Procedes de traitement d'articulations cibles dans l'arthrite inflammatoire utilisant des vecteurs aav vectors codant pour un antagoniste du tnf
WO2008006118A2 (fr) * 2006-07-07 2008-01-10 Bioassets Development Corporation Nouveaux schémas posologiques destinés au traitement de maladies et de troubles
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
EP2395077A1 (fr) 2006-11-03 2011-12-14 Wyeth LLC Substances inhibant la glycolyse dans une culture de cellules
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
WO2009126564A1 (fr) 2008-04-07 2009-10-15 Bayer Healthcare Llc Procédés de production recombinante de glycoprotéines
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
HUE046670T2 (hu) 2010-01-15 2020-03-30 Kirin Amgen Inc Anti IL-17RA ellenanyag kiszerelés és terápiás rendek pikkelysömör kezelésére
WO2012006635A1 (fr) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Molécules à chaîne unique pouvant être traitées et polypeptides faits à partir de celles-ci
WO2012019160A1 (fr) 2010-08-05 2012-02-09 Amgen Inc. Dipeptides pour améliorer le rendement et la viabilité de cultures cellulaires
CN102382850A (zh) * 2010-09-01 2012-03-21 山东新时代药业有限公司 新型人肿瘤坏死因子受体-Fc融合基因及其产物蛋白
WO2012145682A1 (fr) 2011-04-21 2012-10-26 Amgen Inc. Méthode de culture de cellules de mammifère pour améliorer la production de protéines recombinantes
EP2718328A4 (fr) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions et procédés pour augmenter la demi-vie sérique
KR102558247B1 (ko) 2011-07-01 2023-07-24 암젠 인크 포유동물 세포 배양
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
JP2014529473A (ja) 2011-09-02 2014-11-13 アムジエン・インコーポレーテツド 医薬製品および医薬製品の露光を分析する方法
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
EP2771294B1 (fr) 2011-10-25 2017-12-13 Corning Incorporated Contenants en verre pharmaceutique résistant à l'effritement contenant des ingrédients pharmaceutiques actifs
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
ES2657377T3 (es) 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept plegado correctamente con alta pureza y excelente rendimiento
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
TWI625390B (zh) 2013-03-14 2018-06-01 安美基公司 用於增加重組蛋白質之甘露糖含量之方法
LT3395423T (lt) 2013-03-14 2023-12-11 Amgen Inc. Pratekančių giminingumo gryninimo ligandų pašalinimas
TWI683666B (zh) 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
MX2016005572A (es) 2013-10-31 2016-12-09 Amgen Inc Uso de monensina para regular la glicosilacion de proteinas recombinantes.
US10513723B2 (en) 2014-01-13 2019-12-24 Amgen Inc. Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins
KR102519540B1 (ko) 2014-01-29 2023-04-10 암젠 인크 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
AU2015241373B2 (en) 2014-03-31 2020-11-05 Amgen K-A, Inc. Methods of treating nail and scalp psoriasis
ES2909630T3 (es) 2014-06-04 2022-05-09 Amgen Inc Métodos de recolección en cultivos de células de mamífero
WO2016081770A1 (fr) 2014-11-19 2016-05-26 Amgen Inc. Quantification de la fraction glycane dans des glycoprotéines recombinantes
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
KR20170138426A (ko) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
KR20210005689A (ko) 2018-05-01 2021-01-14 암젠 인크 조절된 글리칸 프로파일을 갖는 항체
US11952399B2 (en) 2018-12-18 2024-04-09 Amgen Inc. Methods for purifying proteins
WO2023129974A1 (fr) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Génération de lignées de cellules avec site d'intégration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
JPS61293924A (ja) * 1985-06-23 1986-12-24 Asahi Chem Ind Co Ltd 生理活性物質の受容タンパク
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
EP0325224B1 (fr) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Procédé de préparation d'analogues de récepteurs sécrétés
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (fr) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
DE69017753T3 (de) * 1989-05-18 2013-06-20 Yeda Research And Development Co., Ltd. Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
EP1132471A3 (fr) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag Protéines liant le TNF
ES2120949T4 (es) * 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells

Also Published As

Publication number Publication date
DE69024291D1 (de) 1996-02-01
DE69024291T2 (de) 1996-10-31
EP0418014B1 (fr) 1995-12-20
GR3019333T3 (en) 1996-06-30
EP0418014A1 (fr) 1991-03-20
DE10075011I1 (de) 2003-06-12
US5395760A (en) 1995-03-07
ATE131871T1 (de) 1996-01-15
ES2080809T3 (es) 1996-02-16
NL300008I1 (nl) 2000-08-01
LU90591I2 (fr) 2000-07-31
DK0418014T3 (da) 1996-01-22
NL300008I2 (nl) 2000-12-01
ES2080809T4 (es) 2012-12-20
USRE36755E (en) 2000-06-27

Similar Documents

Publication Publication Date Title
DE69024291D1 (de) Rezeptoren für Tumornekrosisfaktor-alpha und -beta
CA2065346A1 (fr) Recepteurs .alpha. et .beta. de facteur de necrose tumorale
ES2103706T3 (es) Receptores de interleuquina-4.
ATE169956T1 (de) Dna, die für proteine kodiert, die menschliches il-1 binden
ATE213743T1 (de) Typ-ii-interleukin-1-rezeptoren
ATE365796T1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
DE69016508D1 (de) Interleukin-7-Rezeptoren.
FI103987B1 (fi) Interleukiini-7
HUT57827A (en) Recombinant protein receptor and process for producing same
DK0494260T3 (da) Receptorer for granulocytkolonistimulerende faktor